(lp0
S'Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1159445 ... Business Wire  - Mar 23, 2012 NEWTON, Mass.----Galectin Therapeutics Inc.  today announced the pricing of an underwritten public offering of 1,159,445 units at a price to the public of $9.00 per unit, with each unit consisting of two common voting&nbsp;...'
p1
aS"BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics Reuters - Jan 18, 2017 LONDON, March 14 Unilever CEO Paul Polman said there should be a level playing field for companies facing takeover bids such as Kraft Heinz's failed $143 billion attempt to buy the Anglo-Dutch company, the FT reported on Tuesday."
p2
aS'GALECTIN THERAPEUTICS INC.  Files An 8-K Entry into a Material ... Market Exclusive - Dec 29, 2016 Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer.'
p3
aS"analysts Recommendations: Galectin Therapeutics, Inc.  News Oracle - Feb 7, 2017 Galectin Therapeutics, Inc.  will report its next earnings on Mar 13 - Mar 17 . The company reported the earnings of $-0.19/Share in the last quarter where the estimated EPS by analysts was $-0.22/share. The difference between the&nbsp;...Investors Watch-List Stock: Galectin Therapeutics, Inc.'s  - Street UpdatesGalectin Therapeutics to Present at BIO CEO &amp; Investor Conference - PharmiWeb.com "
p4
aS'Gainers &amp; Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX... Nasdaq - Feb 8, 2017 Non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, will be issued in the offering.'
p5
aS'Allergan to buy Tobira in push for fatty liver disease drugs Reuters UK - Sep 20, 2016 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Just ...'
p6
aS'Gainers &amp; Losers Of The Day: ZSAN, EVOK, ARDX, EARS, NEOT... Nasdaq - Feb 16, 2017 Recent event: On Feb.13, the company announced that its pivotal phase III efficacy study of M207 in migraine met endpoints.'
p7
aS"Gainers &amp; Losers Of The Day: PULM, AQB, GALE, PETX, KTOV... RTT News - Feb 7, 2017 The company's lead compound is Emricasan, for the treatment of patients with chronic liver disease. A phase IIb trial of Emricasan in NASH cirrhosis patients, dubbed ENCORE-LF, is expected to be initiated in the second half of this year."
p8
aS'Intercept Pharmaceuticals Announces Initiation Of REGENERATE Trial For ... Clinical Leader - Sep 29, 2015 New York, NY  - Intercept Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases,&nbsp;...'
p9
aS'Pipeline Insights on Nonalcoholic Steatohepatitis Market MarketWatch - Sep 12, 2016 Companies discussed in this Non-Alcoholic Steatohepatitis Pipeline Review, H2 2016 report include Akarna Therapeutics Ltd., AlbireoPharma, Alnylam Pharmaceuticals, Inc., Amunix Operating Inc., Aquinox Pharmaceuticals Inc., Arisaph Pharmaceuticals, Inc ...'
p10
a.